Source: Fox News
Summary
The FDA has approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for treating high cholesterol. The medication blocks the action of PCSK9, a protein that affects how the liver removes LDL (“bad”) cholesterol from the bloodstream. In phase 3 clinical trials, Lipfendra was shown to reduce LDL cholesterol by 56% to 60% when combined with statin therapy. The pill is generally well-tolerated, with diarrhea and dizziness being the most common side effects.
Our Reading
This guidance has been heard before.
The recommendation enters another phase with the approval of Lipfendra, a new treatment option for millions of Americans with high cholesterol. The pill is the first once-daily oral PCSK9 inhibitor, offering an alternative to injectable PCSK9 inhibitors like Repatha and Praluent. Additional research is needed to determine whether Lipfendra reduces the risk of heart attacks, strokes, and cardiovascular deaths. The lower the better when it comes to LDL cholesterol, especially in those at risk for heart disease.
It seems like every few years, we’re reminded that the battle against high cholesterol is ongoing, with new treatments emerging and old ones being reevaluated.
Author: Evan Null
